Alegre-Zurano, LaiaLópez-Arnau, RaúlLuján, Miguel Á.Camarasa García, JordiValverde, O.2022-03-112022-03-112021-08-021661-6596https://hdl.handle.net/2445/184033: 3,4-Methylenedioxypyrovalerone (MDPV) is a new psychoactive substance (NPS) and the most widespread and life-threatening synthetic cathinone of the "bath salts". Preclinical research has proven the cocaine-like psychostimulant effects of MDPV and its potential for abuse. Cannabidiol (CBD) is a non-psychotropic phytocannabinoid that has emerged as a new potential treatment for drug addiction. Here, we tested the effects of CBD (20 mg/kg) on MDPV (2 mg/kg)-induced conditioned place preference and MDPV (0.05 and 0.075 mg/kg/infusion) self-administration paradigms. In addition, we assessed the effects of the co-administration of CBD and MDPV (3 and 4 mg/kg) on anxietylike behaviour using the elevated plus maze (EPM). CBD mitigated the MDPV-induced conditioned place preference. On the contrary, CBD administration throughout the MDPV (0.075 mg/kg/infusion) self-administration increased drug-seeking and taking behaviours, but only in the high-responders group of mice. Furthermore, CBD exerted anxiolytic-like effects, exclusively in MDPV-treated mice. Taken together, our results indicate that CBD modulation of MDPV-induced motivational responses in mice varies depending on the requirements of the learning task, resulting in a complex response. Therefore, further research attempting to decipher the behavioural and molecular interactions between CBD and MDPV is needed.14 p.application/pdfengcc-by (c) Alegre-Zurano, Laia et al., 2021https://creativecommons.org/licenses/by/4.0/CànnabisAnsietatFarmacologiaCannabisAnxietyPharmacologyinfo:eu-repo/semantics/article7165862022-03-11info:eu-repo/semantics/openAccess